Altimmune Faces Legal Challenges as Key Clinical Data Approaches

Altimmune finds itself navigating turbulent waters as multiple class-action lawsuits cast a shadow over the company’s stock performance. The litigation alleges the biopharmaceutical firm made misleading statements regarding the efficacy and trial data for its lead drug candidate, pemvidutide.

Legal Deadlines and Market Pressure

Investors are facing a critical deadline of October 6, 2025, to register as lead plaintiffs in these consolidated actions. The suits focus on allegedly false statements made between August 2023 and June 2025. Central to the dispute are the topline results from the IMPACT Phase 2b trial, with plaintiffs contending that Altimmune failed to achieve its primary endpoint of fibrosis improvement with statistical significance, attributing this shortfall to an unexpectedly high placebo response.

The market delivered a harsh verdict when these study results were released on June 26, 2025. Shares plummeted 53.2%, declining from $7.71 to $3.61 per share—a stark demonstration of biotechnology stocks’ sensitivity to clinical trial outcomes.

Maintaining Analyst Confidence Amid Challenges

Despite these legal headwinds, investment firm H.C. Wainwright has reaffirmed its Buy rating on Altimmune. On September 19, the firm maintained its $12.00 price target, citing anticipated 48-week data from the IMPACT study expected in the fourth quarter of 2025 as a crucial factor in this assessment.

The recent acquisition of 89bio by Roche for approximately $3.5 billion highlights the substantial market potential in MASH (metabolic dysfunction-associated steatohepatitis) therapeutics. This transaction suggests the market could support multiple successful treatments—a potentially favorable development for Altimmune’s prospects.

Key Investor Milestones:
* October 6, 2025: Lead plaintiff deadline for class-action litigation
* Q4 2025: Expected 48-week data from IMPACT Phase 2b trial
* Q4 2025: Scheduled End-of-Phase 2 meeting with FDA
* September 16, 2025: Appointment of Linda M. Richardson as Chief Commercial Officer

Should investors sell immediately? Or is it worth buying Altimmune?

Strengthening Commercial Capabilities

The company has bolstered its leadership team with the September 16 appointment of Linda M. Richardson as Chief Commercial Officer. This strategic hire aims to enhance Altimmune’s commercial infrastructure, particularly important as pemvidutide potentially advances toward Phase 3 development.

Richardson brings over three decades of experience in sales, marketing, and commercial development. Her expertise in metabolic diseases and hepatology positions her to potentially translate Altimmune’s scientific advancements into a competitive commercial strategy.

Pipeline Progress Continues

Beyond the legal proceedings, Altimmune continues to advance its clinical programs. The 24-week data from the IMPACT study demonstrated promising outcomes: up to 59.1% of patients achieved MASH resolution with pemvidutide treatment, accompanied by significant weight reduction.

Emerging data suggests potentially industry-leading improvements in cT1 imaging—an important biomarker for liver inflammation and fibrosis.

Additionally, pemvidutide has received Fast Track designation from the FDA for alcohol use disorder. The Phase 2 RECLAIM and RESTORE trials for this indication were initiated in May and July of 2025.

Financially, the company maintains a solid position. Altimmune reported a second-quarter 2025 EPS of -$0.27, beating expectations of -$0.31. Cash and equivalents stood at $183.1 million—representing a 39% increase since the end of 2024.